Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma pa...
Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study
About this item
Full title
Author / Creator
Rahman, Mohummad A. , Brekke, Jorunn , Arnesen, Victoria , Hannisdal, Marianne H. , Navarro, Andrea G. , Waha, Andreas , Herfindal, Lars , Rygh, Cecilie B. , Bratland, Eirik , Brandal, Petter , Haasz, Judit , Oltedal, Leif , Miletic, Hrvoje , Lundervold, Arvid , Lie, Stein A. , Goplen, Dorota and Chekenya, Martha
Publisher
Bognor Regis: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Bognor Regis: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
Glioblastoma (GBM) is an aggressive malignant brain tumor where median survival is approximately 15 months after best available multimodal treatment. Recurrence is inevitable, largely due to O6 methylguanine DNA methyltransferase (MGMT) that renders the tumors resistant to temozolomide (TMZ). We hypothesized that pretreatment with bor...
Alternative Titles
Full title
Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_6667890c0064459f9f27a9dbdca009cb
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6667890c0064459f9f27a9dbdca009cb
Other Identifiers
ISSN
2050-4527
E-ISSN
2050-4527
DOI
10.1002/iid3.315
